These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome. Steeves TD; Fox SH Prog Brain Res; 2008; 172():495-513. PubMed ID: 18772048 [TBL] [Abstract][Full Text] [Related]
3. Emmetropization: a vision-dependent phenomenon. Rabin J; Van Sluyters RC; Malach R Invest Ophthalmol Vis Sci; 1981 Apr; 20(4):561-4. PubMed ID: 7216673 [TBL] [Abstract][Full Text] [Related]
4. Dopaminergic receptor D5 mRNA expression is increased in circulating lymphocytes of Tourette syndrome patients. Ferrari M; Termine C; Franciotta D; Castiglioni E; Pagani A; Lanzi G; Marino F; Lecchini S; Cosentino M; Balottin U J Psychiatr Res; 2008 Nov; 43(1):24-9. PubMed ID: 18329046 [TBL] [Abstract][Full Text] [Related]
5. Functional imaging of dopaminergic neurotransmission in Tourette syndrome. Segura B; Strafella AP Int Rev Neurobiol; 2013; 112():73-93. PubMed ID: 24295618 [TBL] [Abstract][Full Text] [Related]
8. No evidence for a major gene effect of the dopamine D4 receptor gene in the susceptibility to Gilles de la Tourette syndrome in five Canadian families. Barr CL; Wigg KG; Zovko E; Sandor P; Tsui LC Am J Med Genet; 1996 May; 67(3):301-5. PubMed ID: 8725747 [TBL] [Abstract][Full Text] [Related]
9. Polygenic inheritance of Tourette syndrome, stuttering, attention deficit hyperactivity, conduct, and oppositional defiant disorder: the additive and subtractive effect of the three dopaminergic genes--DRD2, D beta H, and DAT1. Comings DE; Wu S; Chiu C; Ring RH; Gade R; Ahn C; MacMurray JP; Dietz G; Muhleman D Am J Med Genet; 1996 May; 67(3):264-88. PubMed ID: 8725745 [TBL] [Abstract][Full Text] [Related]
10. Refractive errors in an urban population in Southern India: the Andhra Pradesh Eye Disease Study. Dandona R; Dandona L; Naduvilath TJ; Srinivas M; McCarty CA; Rao GN Invest Ophthalmol Vis Sci; 1999 Nov; 40(12):2810-8. PubMed ID: 10549640 [TBL] [Abstract][Full Text] [Related]
11. Dopaminergic agents affect the ability of brief periods of normal vision to prevent form-deprivation myopia. McCarthy CS; Megaw P; Devadas M; Morgan IG Exp Eye Res; 2007 Jan; 84(1):100-7. PubMed ID: 17094962 [TBL] [Abstract][Full Text] [Related]
12. Effects of continuous light on experimental refractive errors in chicks. Guo SS; Sivak JG; Callender MG; Herbert KL Ophthalmic Physiol Opt; 1996 Nov; 16(6):486-90. PubMed ID: 8944195 [TBL] [Abstract][Full Text] [Related]
13. Neuroleptic effects in Tourette syndrome predict dopamine excess and acetylcholine deficiency. Stahl SM; Berger PA Biol Psychiatry; 1982 Sep; 17(9):1047-53. PubMed ID: 6128037 [TBL] [Abstract][Full Text] [Related]
16. Recent advances in Gilles de la Tourette syndrome: implications for clinical practice and future research. Leckman JF; Cohen DJ Psychiatr Dev; 1983; 1(3):301-16. PubMed ID: 6324164 [TBL] [Abstract][Full Text] [Related]
17. Features resembling Tourette's syndrome in developmental stutterers. Abwender DA; Trinidad KS; Jones KR; Como PG; Hymes E; Kurlan R Brain Lang; 1998 May; 62(3):455-64. PubMed ID: 9593619 [TBL] [Abstract][Full Text] [Related]
18. Dopaminergic dsyfunction in Tourette syndrome. Singer HS; Butler IJ; Tune LE; Seifert WE; Coyle JT Ann Neurol; 1982 Oct; 12(4):361-6. PubMed ID: 6184010 [TBL] [Abstract][Full Text] [Related]
19. Different visual deprivations produce different ametropias and different eye shapes. Gottlieb MD; Fugate-Wentzek LA; Wallman J Invest Ophthalmol Vis Sci; 1987 Aug; 28(8):1225-35. PubMed ID: 3610540 [TBL] [Abstract][Full Text] [Related]
20. Increased prefrontal D2 protein in Tourette syndrome: a postmortem analysis of frontal cortex and striatum. Minzer K; Lee O; Hong JJ; Singer HS J Neurol Sci; 2004 Apr; 219(1-2):55-61. PubMed ID: 15050438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]